Tyrosine phosphorylation is tightly regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), and has a critical role in malignant transformation and progression. Although PTKs have a well-established role in regulating breast cancer growth, contribution of PTPs remains mostly unknown. Here, we report that the tyrosine phosphatase PTPH1 stimulates breast cancer growth through regulating vitamin D receptor (VDR) expression. PTPH1 was shown to be overexpressed in 49% of primary breast cancer and levels of its protein expression positively correlate with the clinic metastasis, suggesting its oncogenic activity. Indeed, PTPH1 promotes breast cancer growth by a mechanism independent of its phosphatase activity, but dependent of its stimulatory effect on the nuclear receptor VDR protein expression and depletion of induced VDR abolishes the PTPH1 oncogenic activity. Additional analyses showed that PTPH1 binds VDR and increases its cytoplasmic accumulation, leading to their mutual stabilization and stable expression of a nuclear localization-deficient VDR abolishes the growth-inhibitory activity of the receptor independent of 1,25-dihydroxyvitamin D3. These results reveal a new paradigm in which a PTP may stimulate breast cancer growth through increasing cytoplasmic translocation of a nuclear receptor, leading to their mutual stabilization.
Introduction
Reversible tyrosine phosphorylation is controlled by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), which together regulates important signal transduction pathways in control of cell growth, invasion and transformation (Ostman et al., 2006) . Abnormal tyrosine phosphorylation can lead to various human diseases including cancers and many oncogenes have in fact been found to be hyperactively mutated or overexpressed PTKs. In breast cancers, for example, the human epidermal growth factor receptor 2 (Her-2), a membrane PTK, is overexpressed in about 25% of the diseases and its expression levels are strongly associated with the poor prognosis (Slamon et al., 1987) . The therapeutic intervention against the Her-2 signaling has consequently become an important strategy to control breast cancer progression (Yu and Huang, 2000) . Roles of PTPs in human breast cancer, on the other hand, remain mostly unexplored. The phosphatase SHP1, for example, is overexpressed in 58% of primary breast cancer (Yip et al., 2000) , but whether SHP1 can promote human breast cancer growth has not been established (Ostman et al., 2006) . Studies of PTPs for their roles in regulating breast cancer growth are therefore highly warranted. PTPH1 (also called PTPN3) is a 120-kDa protein that belongs to the nontransmembrane PTP superfamily (Yang and Tonks, 1991) . Previous genetic analysis showed that PTPH1 and its several family members are mutated in human colon cancer, but the functional consequence of these mutations remains unestablished (Wang et al., 2004) . Our recent studies showed that p38g, a p38 mitogen-activated protein kinase family member, increases Ras oncogenesis independent of phosphorylation (Tang et al., 2005) and PTPH1 dephosphorylates and cooperates with p38g to promote Ras oncogenesis through a complex formation . Importantly, PTPH1 was found to be overexpressed in primary human colon cancer and its depletion inhibits colon cancer growth . In this report, we tested the hypothesis that PTPH1 may also positively regulate breast cancer growth. Our results showed that PTPH1 is overexpressed in about 49% of primary human breast cancer and its expression levels positively correlate the clinic metastasis. PTPH1 was further shown to increase breast cancer growth by a mechanism independent of phosphatase activity, but dependent of its stimulatory effect on vitamin D receptor (VDR) protein expression. Additional experiments revealed that PTPH1 binds VDR and increases its cytoplasmic accumulation lead-ing to their mutual stabilization and stable expression of a nuclear localization-deficient VDR abolishes its growth-inhibitory activity independent of 1,25-dihydroxyvitamin D3 (vitamin D3). These results indicate that the tyrosine phosphatase PTPH1 may stimulate breast cancer growth through a positive feedback loop, involving stimulating VDR protein expression and increasing its cytoplasmic accumulation, leading to their mutual stabilization via a complex formation. Targeting PTPH1 expression and/or regulating VDR localizations may be a novel approach to control human breast cancer progression.
Results
PTPH1 is overexpressed in primary human breast cancer and its protein expression levels positively correlate with the lymph node metastasis To investigate roles of PTPH1 in breast cancer, a group of primary breast cancer tissues was analyzed by immunohistochemistry for PTPH1 protein expression with a specific antibody . Results in Figure 1 showed that PTPH1 protein is overexpressed in breast cancer specimens over their matched normal tissues with about 50% of tumor samples having an increased PTPH1 expression. In addition, levels of increased PTPH1 protein expression are significantly higher in lymph node metastatic tumors, indicating that PTPH1 may have a promoting role in human breast cancer growth and progression. Moreover, PTPH1 expression appears to be higher in invasive ductal over lobular carcinomas (Figures 1a and b) , albeit a statistically significant difference was not reached because of the limited number of specimens analyzed. As there are distinct clinical profiles and gene-expression pathways in these two types of breast cancers (Korkola et al., 2003) and patients with estrogen receptor-negative (ERÀ) ductal carcinoma are associated with a worse survival than their counterparts with lobular tumor (Mhuircheartaigh et al., 2006) , PTPH1 may have a particular role in more malignant ductal carcinomas. These results together indicate a role of PTPH1 in clinical breast cancer metastasis and progression.
PTPH1 signals independent of p38g in breast cancer, but specifically regulates the nuclear receptor VDR protein expression Our recent studies showed that both Ras and p38g induce PTPH1 protein expression , and we therefore next examined whether p38g stimulates PTPH1 expression as compared with its family member p38a through adenovirus-mediated gene overexpression.
To study effects of PTPH1 on p38 mitogen-activated protein kinase signaling, breast cancer cells were engineered to express tetracycline-inducible (Tet-on) PTPH1 (Qi et al., 2006) and its effects on endogenous, as well as ectopically expressed p38s, were examined by western blot (WB). Results in Figure 2a showed that in contrast to rat epithelial intestinal IEC-6 cells , p38g overexpression has no substantial effects on endogenous PTPH1 expression. In a similar PTPH1 requires VDR to stimulate breast cancer growth H-Y Zhi et al manner, Tet inducible PTPH1 in ERÀ 231 and ER þ MCF-7 cells does not significantly impact p38g expression. These results indicate that PTPH1 may signal independent of p38g in these breast cancer cells under the current experimental conditions.
Nuclear receptors have an important role in regulating breast cancer growth via ligand-dependent and -independent pathways, with ERa and progesterone receptor generally considered proliferative and VDR anti-proliferative (Conzen, 2008) . We therefore next examined whether PTPH1 may affect protein expression of nuclear receptors by WB analyses. Results in Figures 2b-e, 3d, 4b, 5a and b showed that PTPH1-forced expression upregulates VDR, whereas its depletion decreases levels of VDR protein expression without consistent effects on ER or progesterone receptor in this group of cell lines. The signaling specificity between PTPH1 and VDR was further demonstrated in 293T cells through coexpressions ( Figure 2d ) in which only the ectopically expressed VDR (but not ER or progesterone receptor-B) is elevated by co-transfected PTPH1, but not Wip1, a serine/threonine phosphatase previously found to have a role in breast cancer growth (Bulavin et al., 2004) . Additional experiments showed that PTPH1 increases VDR protein but not RNA expression (Figures 2e and f) . These results together indicate that PTPH1 positively regulates VDR protein (but not RNA) expression, which may have an important role in regulating breast cancer growth.
PTPH1 increase of breast cancer growth is independent of phosphatase activity, but coupling with its regulatory effects on VDR protein expression The tyrosine phosphatases PTP1B and SHP1 are overexpressed in human breast cancer (Wiener et al., 1994; Yip et al., 2000) and PTP1B was recently further shown to be required for Her-2-induced transformation in vitro (Arias-Romero et al., 2009 ) and mammary tumor formation in vivo (Bentires-Alj and Neel, 2007) . However, thus far, there have been no functional studies about their roles in regulating human breast cancer growth. We therefore examined whether PTPH1 may promote human breast cancer growth. Results in Figure 3a showed that stable expression of PTPH1 and its phosphatase-deficient mutant PTPH1/DA (Zhang et al., 1999) in ERÀ 231 cells increases colony formation, indicating a promoting role of PTPH1 in breast cancer growth independent of phosphatase activity. A similar growth-stimulatory effect was further demonstrated in ER þ T47D cells by lentiviral- Figure 2 PTPH1 increases VDR but not ER or progesterone receptor protein expression. (a) p38g fails to increase PTPH1 expression in breast cancer cells. Tet-on PTPH1 cells were infected with adenoviruses expressing b-galactosidase (Gal) or p38a/g and examined for protein expression by WB (no phosphorylated p38g and p38a were detected under this condition). (b) PTPH1 increases VDR protein expression. Cells were cultured with and without Tet for indicated time and examined for protein expression. (c) PTPH1 depletion specifically decreases VDR expression. Cells were stably depleted of PTPH1 protein expression by lentiviral infection and examined for protein expression. (d) A specific stimulation of VDR protein expression by coexpressed PTPH1 in 293T cells. Cells were transiently transfected with indicated constructs and assessed for protein expression 24 h later. (e, f) PTPH1 increases VDR protein but not RNA expression. T47D cells were stably expressed with PTPH1 by lentiviral infection, which were then examined for VDR protein expression by western blot (e) and for VDR RNA expression by quantitative reverse transcription-PCR (f). GADPH, glyceraldehyde 3-phosphate dehydrogenase; shRNA, small hairpin RNA. mediated PTPH1 overexpression ( Figure 3b ) and in ER þ MCF-7 and ERÀ 231 cells by Tet-induced PTPH1 expression ( Figure 3c ), suggesting that PTPH1 increases breast cancer growth independent of ER expression. Furthermore, stable PTPH1 depletion by lentiviral-mediated small hairpin RNA delivery inhibits the colony formation in T47D and MCF-7 cells, which couples with a decreased VDR protein expression ( Figure 3d ). These results together indicate that PTPH1 stimulates breast growth independent of phosphatase activity, likely through a mechanism affecting VDR protein expression.
VDR is required for PTPH1 to stimulate breast cancer growth A positive regulation of VDR protein expression by PTPH1, suggests that VDR may be required for PTPH1 oncogenic activity. To examine this possibility, VDR was depleted from T47D cells stably expressing PTPH1 by small interfering RNA and its effect on colony formation was examined. Results in Figures 4a and b (left panel) showed that silencing VDR gene expression alone increases the colony formation and decreases endogenous PTPH1 expression, indicating that PTPH1-forced expression increases colony formation. PTPH1 and/or its phosphatase-deficient mutant was expressed in breast cancer cells via stable transfection or infection or Tet-on system as indicated and modified cells were examined for protein expression (insets) and colony formation (mean of at least three separate experiments, bars, s.e., the same for all other colony-formation and proliferation assays, *Po0.05 vs vector or Lac-Z or no Tet control). (d) PTPH1 depletion decreases VDR expression and inhibits breast cancer growth. Cells were stably depleted of PTPH1 by lentiviral small hairpin RNA and assessed for protein expression (insets) and colony formation (*Po0.05 vs respective control). GADPH, glyceraldehyde 3-phosphate dehydrogenase.
Figure 4 PTPH1 requires VDR to increase breast cancer growth. (a, b (left)) VDR depletion blocks PTPH1 stimulation of human breast cancer growth. The vector and PTPH1 stably transfected cells were incubated with control and VDR small interfering RNA (siRNA) oligos for 48 h, which were then analyzed for protein expression and colony formation (*Po0.05 vs Lac-Z plus control oligo; **Po0.05 vs PTPH1 or VDR siRNA and P40.05 vs Lac-Z plus control oligo). (b (right), c) PTPH1 only increases proliferation in VDR-expressed mouse breast cancer cells. VDR þ / þ and VDRÀ/À cells were stably expressed with PTPH1 by lentiviral infection and analyzed for protein expression and cell proliferation at 48 and 72 h after plating by a fluorescence plate reader (*Po0.05 vs Lac-Z control). GADPH, glyceraldehyde 3-phosphate dehydrogenase.
PTPH1 requires VDR to stimulate breast cancer growth H-Y Zhi et al endogenous VDR is growth inhibitory and may also be required for endogenous PTPH1 expression. Importantly, reducing VDR protein expression to a level similar to the vector control completely blocks PTPH1induced growth stimulation (lane 4 vs 1 from left in Figures 4b (left panel) and a). These results indicate a required role of induced VDR in PTPH1 stimulation of breast cancer growth.
To further demonstrate the role of VDR in PTPH1stimulated breast cancer growth, mouse VDR knockout (VDRÀ/À) mammary tumor cells and the wild-type counterparts (VDR þ / þ ; Zinser et al., 2003) were next stably expressed with PTPH1 by lentiviral infection and analyzed for cell growth. Because these cells failed to form colonies (Zinser et al., 2003) , the growth was estimated by the cyquant NF cell proliferation assay (Invitrogen, Sunnyvale, CA, USA). Of great interest, the PTPH1-forced expression only increases the growth of VDR þ / þ but not VDRÀ/À cells (Figure 4c ), further indicating the role of endogenous VDR in PTPH1promoting breast cancer growth. However, WB analyses from these cells showed that endogenous PTPH1 protein expression was undetectable in VDRÀ/À cells compared with the WT counterparts and the PTPH1 stable expression failed to increase VDR protein expression in both lines (Figure 4b , right panel). These results further indicate that endogenous VDR is required for PTPH1 protein expression, and suggest that PTPH1 induction of VDR protein expression may be species specific. Nevertheless, results from both human and mouse breast cancer cells are consistent with the conclusion that PTPH1 requires VDR to stimulate breast cancer growth.
PTPH1 binds VDR and increases its cytoplasmic expression leading to their mutual stabilization VDR expression and activation in human cancer generally lead to a growth-inhibitory response (Campbell et al., 2000; Qi et al., 2002; Maruyama et al., 2006) . Although classically considered as a nuclear receptor, VDR has been shown to be shuttle between the cytoplasm and the nucleus through interacting with other proteins Yasmin et al., 2005) . VDR activations by ligand vitamin D3 (Racz and Barsony, 1999) and its partner retinoid X receptor (Prufer et al., 2000) are also known to facilitate its nuclear localization, and a decreased VDR nuclear localization can lead to a suppressed VDR transcription activity and a resistance to vitamin D-induced growth inhibition (Yang et al., 2001; Garay et al., 2007) . To understand why PTPH1 increases breast cancer growth and concomitantly stimulates expression of the growthinhibitory protein VDR, cellular VDR distributions were examined in response to PTPH1 depletion and expression by cell fractionation analyses. Results in Figure 5a showed that endogenous PTPH1 is exclusively cytoplasmic and there was a decreased VDR protein expression in cytoplasmic, but not nuclear compartments, following the PTPH1 depletion. In addition, the ectopically expressed PTPH1 also only present in the cytoplasm, which again led to an increased VDR protein expression in the cytosolic fraction without affecting its nuclear concentration (Figure 5b ). Similar PTPH1regulatory effects on cytoplasmic VDR protein expression were also observed after cells were cultured with vitamin D3 (Figures 5a and b, bottom) . These results together indicate that PTPH1 is exclusively cytoplasmic, and only cytoplasmic VDR is sensitive to PTPH1 regulations independent of ligand.
Previous studies showed that increases of VDR cytoplasmic accumulation by mutations of its nuclear localization signal (NLS) inhibit VDR transcriptional activity (Prufer et al., 2000) . We sought next to determine wherther the PTPH1-resultant increase in cytoplasmic VDR also regulates VDR transcriptional activity. In this case, T47D cells stably expressing PTPH1 were transiently transfected with a vitamin D response element (VDRE)-Luc (Ward et al., 2001; Li et al., 2007) by including an estrogen response element (ERE)-Luc (Obrero et al., 2002; Qi et al., 2004) for comparison and luciferase activity was determined 2 days later. Results in Supplementary Figure S1a showed that PTPH1 significantly inhibits the VDRE activity without affecting the ERE-dependent transcription. The VDRE suppressive role was further consolidated by a decreased RNA expression of CYP24, a VDR target gene, in PTPH1 expressed cells (Figure 5d ). Incubation of cells with vitamin D3, however, switched the VDREsuppressive effect of PTPH1 into a stimulatory response without significant impacts on its inhibition of CYP24 expression (Figures 5c and d) . This difference may be, in part, due to the fact that the VDRE-Luc is an artificial luciferase reporter driven by two VDRE repeats from osteopontin (opn) gene (Ward et al., 2001) , and vitamin D3 can even distinctively regulate histone acetylation on endogenous opn and cyp24 promoters (Kim et al., 2005) . These results indicate that increased PTPH1 expression and resultant cytoplasmic VDR accumulation may together lead to a decreased VDR transcriptional activity in the absence of vitamin D3.
To explore whether PTPH1 may increase cytoplasmic VDR expression through a complex formation, V5tagged VDR was coexpressed with PTPH1 and its DA mutant, and V5 precipitates were examined for PTPH1 protein expression. Results in Figure 6a showed that both PTPH1 and PTPH1/DA bind VDR proteins. Additional experiments revealed that VDR also binds PTPH1 in vitro and incubation of cells with vitamin D3 does not significantly affect their binding (Supplementary Figures S1c and S2) . To demonstrate whether a complex formation regulates their stability, VDR and PTPH1 protein stability were analyzed with and without PTPH1 overexpression in T47D and VDR þ / þ and VDRÀ/À breast cancer cells, as described . Results in Figure 6b showed that the PTPH1 expression increases VDR protein stability, indicating that PTPH1 may upregulate VDR by increasing its protein stability. More interestingly, the ectopically expressed PTPH1 is more stable in VDR þ / þ cells than in its knockout counterparts (Figure 6c ), suggesting that endogenous VDR also stabilizes PTPH1 protein. Similar results were also obtained in the presence of vitamin D3 ( Supplementary Figures S1d  and e ). These results together indicate that the cytoplasmic PTPH1 may bind and stabilize VDR independent of vitamin D3, leading to their mutual stabilization and enhanced breast cancer growth by a positive feedback (Figure 7e ).
VDR requires its nuclear localization to inhibit breast cancer growth
The coupling of PTPH1-stimulated breast cancer growth with its increases of cytoplasmic VDR accumulation promoted us next to examine whether VDR alone regulates cell growth dependent of its cellular localization. In this regard, a mutant VDR (VDR/mNLS) was generated by changing three amino acids on its NLS, as previously described (Prufer et al., 2000) , and stably expressed in T47D cells through antibiotic selection together with a wild-type VDR for comparison. Cell fractionation and immunostaining analyses showed that in contrast to the wild-type receptor this mutant is mostly localized in the cytoplasm and much less responsive to vitamin D3-induced nuclear translocation (Figures 7b and Supplementary Figure S3 ), as previously described (Prufer et al., 2000) . Consistent with the notion that cytoplasmic VDR may cooperate with PTPH1 to promote breast cancer growth through a complex formation (Figure 7e ), the NLS-mutated receptor appears to have a stronger affinity in binding endogenous PTPH1 compared with the wild-type protein (Figure 7a ). Most importantly, the mutant expressed cells grew significantly faster than those expressing the wild-type VDR by short-term proliferation and long-term colony-formation assays (Figures 7c  and d ). An addition of vitamin D3 did not significantly affect their growth-regulatory activities (Supplementary Figure S1b) . These results indicate that VDR requires its nuclear localization to inhibit breast cancer growth independent of vitamin D3, and thereby, further consolidate our conclusion that cytoplasmic VDR may cooperate with PTPH1 to promote breast cancer growth through their mutual stabilization.
Discussion
The role of PTKs such as Her2 in breast cancer growth has been well established (Yu and Huang, 2000) , whereas the contribution of PTPs has been mostly Figure 6 PTPH1 forms a complex with VDR leading to their mutual stabilization. (a) PTPH1 and its mutant bind VDR protein in 293T cells. (b) PTPH1 increases VDR protein stability in T47D cells. The vector and PTPH1 stably expressed cells were incubated with cycloheximide (CHX, 100 mg/ml) for the time as indicated and analyzed for protein expression (*indicates a non-specific band). (c) VDR increases PTPH1 stability. Cells were transiently expressed with HA-PTPH1 and analyzed for protein expression 48 h later, as described above. GADPH, glyceraldehyde 3-phosphate dehydrogenase.
PTPH1 requires VDR to stimulate breast cancer growth H-Y Zhi et al unexplored. In this report, we showed that the tyrosine phosphatase PTPH1 is overexpressed in primary human breast cancer and its increased protein expression further correlates with the clinical metastasis. Furthermore, PTPH1 was shown to stimulate breast cancer growth independent of phosphatase activity, likely through increasing cytoplasmic VDR protein expression via a complex formation, thereby forming a positive feedback loop leading to their mutual stabilization. This was demonstrated by the following: 1) PTPH1 stimulates breast cancer growth and increases VDR protein expression in several breast cancer cell lines; 2) depletion of induced VDR abolishes the PTPH1 oncogenic activity and PTPH1 also loses its growth stimulatory activity in VDRÀ/À cells; 3) PTPH1 is exclusively cytoplasmic and only regulates cytoplasmic VDR protein expression; 4) PTPH1 binds and stabilizes VDR protein; 5) PTPH1 protein expression is also decreased in VDR depleted or knockout cells, and there is a reduced PTPH1 protein stability in VDRÀ/À cells compared with their VDR þ / þ counterparts, indicating their mutual stabilization effect and 6) a nuclear localization-deficient VDR loses its growth inhibitory activity. Thus, upregulated cytoplasmic VDR may cooperate with PTPH1 to stimulate breast cancer growth through their complex formation and mutual stabilization (Figure 7e ). These results together reveal a new role of a PTP in regulating breast cancer growth through signaling cross talk with a nuclear receptor.
So far only few PTPs have been reported to be involved in regulating breast cancer growth. A tumorsuppressor function, for example, has been proposed for the PTPa that inhibits in vitro breast cancer growth, but is paradoxically overexpressed in 29% of primary breast cancer (Ardini et al., 2000) . The phosphatase PTP1B, on the other hand, is hyperexpressed in primary breast tumors (Wiener et al., 1994) and required for Her-2induced breast epithelial cell transformation in vitro (Arias-Romero et al., 2009) and for Her-2 resultant mammary tumor development in mice (Bentires-Alj and Neel, 2007) . However, PTP1B inhibits the transformation in fibroblasts by Her-2 (Brown-Shimer et al., 1992) and Ras (Liu and Chernoff, 1998) and no studies so far have shown a role of PTP1B in regulating human breast cancer growth. PTPH1, on the other hand, is induced by Ras and overexpressed in primary colon and breast cancers (Figure 1) , and stimulates the malignant growth in both ER þ and ERÀ breast cancers (Figure 3) . To our knowledge, this may be the first report showing that an overexpressed PTP in primary breast tumors acutely promotes human breast cancer growth. Further experiments are needed to investigate whether PTPH1 promotes breast cancer growth in vivo and whether PTPH1 signals through Ras and/or Her-2 to increase breast cancer development and progression.
Our result that a nuclear localization-deficient VDR loses its growth-inhibitory activity is consistent with the conclusion that PTPH1 may increase breast cancer growth through increasing cytoplasmic VDR expression and resultant mutual stabilization. Although previous studies implicate that only nuclear VDR is transcriptional active (Prufer et al., 2000; and/ or growth inhibitory (Yang et al., 2001 ; Garay et al., Figure 7 A nuclear localization-deficient VDR loses its growthinhibitory activity in breast cancer cells. (a) VDR binds PTPH1 in breast cancer cells. T47D cells stably expressed with VDR or its mutant were analyzed for protein complex formation by V5 IP and WB analyses. (b) Regulatory effects of vitamin D3 on VDR and its mutant nuclear translocation. Cells were cultured in the absence and presence of 10 nM vitamin D3 for 24 h and collected for cell fractionation analyses. (c, d) Indicated cells were assessed for proliferation (c) or colony formation (d) (*Po0.05 vs vector or VDR expressed cells) as described in Figures 4c and 3, respectively. (e) PTPH1 stimulates breast cancer growth through increasing cytoplasmic VDR expression. Nuclear VDR is known to be growth inhibitory, whereas our results presented here suggest that cytoplasmic VDR loses this inhibitory function. As PTPH1 promotes breast cancer growth by a mechanism that couples with its activity to bind and stabilize VDR protein and to increase cytoplasmic VDR expression, our results of a VDR-dependent growth stimulation by PTPH1 together with a decreased PTPH1 protein expression/stability in VDR-depleted cells suggest that PTPH1 may increase breast cancer growth through cooperation with cytoplasmic VDR via mutual stabilization. This model suggests that regulation of PTPH1 expression and/or VDR localization may be a new approach to control breast cancer growth and progression. IP, immunoprecipitation. 2007), no studies reported thus far have directly demonstrated a functional role of the NLS in VDRregulated malignant growth. Although VDR/mNLSexpressed cells tend to be more proliferative than the vector control, its enforced expression alone failed to significantly increase breast cancer cell growth ( Figures  7c and d) , indicating that the cytoplasmic receptor may only act to assist other associated oncoproteins, such as PTPH1, to promote the malignant growth. In supporting this speculation, two recent clinical studies showed that increased cytoplamic VDR protein expression in primary lung cancer predicts an advanced stage of the disease (Menezes et al., 2008) and in primary colon cancer correlates with PIK3CA and K-Ras mutations (Kure et al., 2009) . It would be of great interest to investigate further if increased PTPH1 expression in primary breast cancer couples with elevated cytoplasmic VDR expression and whether such combined upregulations predict a poor clinic outcome. Studies of the signaling cross talk between PTPH1 and VDR may reveal a novel strategy for cancer therapeutic targeting by regulating PTPH1 expression and/or VDR localizations.
Materials and methods
Cell lines, constructs, small hairpin RNAs and reagents MCF-7, T47D and 231 (MDA-MB-231) human breast cancer cells were purchased from American Type Culture Collection (Manassas, VA, USA) and maintained as previously described (Qi et al., 2004 (Qi et al., , 2006 . Mouse mammary tumor cell lines from VDR wild-type ( þ / þ ) and knockout (À/À) mice have been previously described (Zinser et al., 2003) . HA-tagged wild-type PTPH1 and its phosphatase-deficient mutant (PTPH1/DA) expression constructs were kindly provided by Dr NK Tonks (Yang and Tonks, 1991; Zhang et al., 1999) . Wip1 expression plasmid was a gift from Dr LA Donehower (Lu et al., 2005) , while progesterone receptor-B expression construct was kindly provided by Dr CR Lange (Lange et al., 2000) . VDR and ER expression plasmids as well as luciferase expression constructs driven by VDRE-Luc or estrogen response element (ERE-Luc) have been previously described (Ward et al., 2001; Obrero et al., 2002; Qi et al., 2006; Li et al., 2007) . A nuclear localization defective VDR (mNLS) was generated by PCR as previously described (Prufer et al., 2000; primers: forward, 5 0 -CTTCTTCAGGCGAAGCATGCAGGGCGAGGCACTA TTCACCTGCCC-3 0 ; reverse: 5 0 -GGGCAGGTGAATAGTG CCTCGCCCTGCATGCTTCGCCTGAAGAAG-3 0 ). Lentivirus systems were purchased from Invitrogen (San Diego, CA, USA) and used to deliver PTPH1 small hairpin RNA as described . The small interfering RNA oligos against human VDR were purchased from Santa Cruz (Santa Cruz, CA, USA) (sc-45920A) and used as a pool (strand A: 5 0 -AUC CGUAGUUCCCUGAAA-3 0 ; strand B: 5 0 -CACGUUCCUU ACUGCAGAA-3 0 ; strand C: 5 0 -GGAACUCCUGGAAAUA UCA-3 0 ) by using a non-target oligo as a control. Modified eagle medium (MEM), serum and other cell culture materials were supplied by Gibco (Grand Island, NY, USA) and chemicals by Sigma (St Louis, MO, USA). 1,25-dihydroxyvitamin D3 (1,25(OH)2D3 or vitamin D3) was supplied by Hoffmann-La Roche (Nutley, NJ, USA). Antibodies used in this study include V5 from Invitrogen, HA from Immunology Consultants Lab (Newberg, OR, USA), p38g from R&D Systems (Minneapolis, MN, USA), and Flag (sc-807), PTPH1 (sc-9789) and GAPDH (sc-47724) were from Santa Cruz. A mouse anti-PTPH1 monoclonal antibody was a gift from Dr NK Tonks.
Gene expression and silencing
The inducible expression system (T-Rex) was purchased from Invitrogen and used to express a full-length human PTPH1 in MCF-7 and MDA-MB-231 cells, as previously described (Qi et al., 2006) . For stable PTPH1 protein expression, cells were either transfected with PTPH1 and PTPH1/DA in a pcDNA3 vector (Qi et al., 2004) or infected with lentiviral PTPH1 , followed by antibiotic selection, whereas Fugene6 was used for transiently expressing PTPH1 in VDR þ / þ and VDRÀ/À cells. To silence PTPH1, the shLuc or shPTPH1 containing lentiviruses were generated in packaging cells and used to infect target cells through antibiotic selection . To express PTPH1 in Tet-on system, cells were incubated with and without Tet overnight and then subjected to various analyses (Qi et al., 2006) .
Colony formation and cyquant NF cell proliferation assays
To determine the long-term effect of PTPH1 on cell growth, colony formation assays were performed as described (Chen and Waxman, 1994) . Briefly, 500 cells were plated per well in 6well plates and colonies formed were stained, photographed and manually counted about 2 weeks later. To assess proliferation of VDR þ / þ and VDRÀ/À mouse breast tumor and PTPH1 expressed human breast cancer T47D cells, 1500 cells were seeded per well in a 96-well plate and cell growth was assessed using the cyquant NF cell proliferation assay kit according to the manufacturer's instructions. Resultant fluorescence signals were measured in a plate reader (Invitrogen, Sunnyvale, CA, USA) with excitation at 485 nm and emission detection at 530 nm. To assess effects of ligand, vitamin D3 was added into the culture at a final concentration of 10 nM with a proper solvent control throughout the entire period.
Human breast cancer specimens and immunohistochemistry All human breast cancer tissues were collected by Department of Pathology, Medical College of Wisconsin with informed consent. The immunohistochemistry analyses were conducted in accordance with Institutional Review Board approval from Medical College of Wisconsin. Briefly, sections of formalinfixed and paraffin-embedded blocks were subjected to immunostaining, as described . A mouse anti-PTPH1 (1:600) was used as primary antibody. Staining intensity and extent were scored independently by two observers and a consensus score was reached and assigned to each case, based on the criteria: 0, negative, 1-4, weak; 5-8, moderate and 9-12, strong staining, as described .
Cell fractionation, Immunoprecipitation and WB analyses
To prepare cell factions, cells were lysed in a buffer containing 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acids (HEPES), pH 7.4, 5 mM KCl, 0.137 mM NaCl, 5.5 mM glucose, 10 mM EDTA, 0.05% Nonidet P-40, 0.1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin and 1 mg/ml aprotinin, followed by incubation at 4 1C for 20 min. Lysates were then centrifuged at 1000 r.p.m. to separate cytoplasmic fraction from nuclei (Qi et al., 2006) . Resultant pellets were washed and re-suspended in 200 ml of buffer containing 1% Triton X-100, 400 mM KCl, 10 mM Tris-HCl, pH 7.5, 0.1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin and 1 mg/ml leupeptin. For immunoprecipitation analyses, cells were washed with cold phosphate-buffered saline and lysed in modified RIPA buffer, which were then incubated with a primary antibody overnight. For cell fractionation, protein concentration in each preparation was measured and the same amount of protein was analyzed by WB, whereas for direct WB, cells were lysed in 1 Â loading buffer and separated by SDS-polyacrylamide gel electrophoresis (Qi et al., 2006) .
Luciferase reporter assays and quantitative reverse transcription PCR For luciferase assay, cells were transiently transfected with VDRE-Luc (Li et al., 2007) or ERE-Luc (Qi et al., 2004) and assayed for luciferase activity using a dual luciferase kit (Promega, Madison, WI, USA) in a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA, USA). To measure VDR and CYP24 expression, total RNAs were prepared by TRIzol and subjected to quantitative real-time reverse transcription PCR analyses (quantitative reverse transcription PCR) using iScriptTM One-Step RT-PCR approach with SYBR Green kit (Bio-Rad Laboratories, Hercules, CA, USA), as described . Primers for VDR are: forward, 5 0 -CTTC AGGCGAAGCATGAAGC-3 0 ; reverse, 5 0 -CCTTCATCATG CCGATGTCC-3 0 and for CYP24: forward, 5 0 -GTGGCTCCA GCCAGACCCTA-3 0 , reverse, 5 0 -GGCGAGGTTGGTACG AGGTG-3 0 and for GAPDH: forward, 5 0 -GGTGGTCTCCT CTGACTTCAACA-3 0 , reverse, 5 0 -GTTGCTGTAGCCAAA TTCGTTGT-3 0 . Results are normalized to GAPDH and expressed as relative to the vector control.
Statistical analysis
Colony numbers, VDRE activity and CYP24 RNA expression were analyzed by Student's t-test or ANOVA for statistical difference. The Kruskal-Wallis test was used to examine the correlation of PTPH1 protein expression with other pathological parameters in primary breast cancers. Increased protein expression (PTPH1) in breast cancer tissues vs matched normal tissues was analyzed by paired t-test.
